Neurocrine Biosciences Past Earnings Performance
Past criteria checks 4/6
Neurocrine Biosciences has been growing earnings at an average annual rate of 13%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 21.3% per year. Neurocrine Biosciences's return on equity is 13.5%, and it has net margins of 16%.
Key information
13.0%
Earnings growth rate
11.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 21.3% |
Return on equity | 13.5% |
Net Margin | 16.0% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Jul 09Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
May 08Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Apr 27Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet
Mar 08Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Dec 08Revenue & Expenses Breakdown
How Neurocrine Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 2,120 | 339 | 908 | 0 |
31 Mar 24 | 1,982 | 370 | 888 | 0 |
31 Dec 23 | 1,887 | 250 | 888 | 0 |
30 Sep 23 | 1,784 | 191 | 852 | 0 |
30 Jun 23 | 1,673 | 176 | 834 | 0 |
31 Mar 23 | 1,599 | 64 | 795 | 0 |
31 Dec 22 | 1,489 | 155 | 753 | 0 |
30 Sep 22 | 1,389 | 58 | 726 | 0 |
30 Jun 22 | 1,297 | 12 | 695 | 0 |
31 Mar 22 | 1,208 | 71 | 655 | 0 |
31 Dec 21 | 1,134 | 90 | 583 | 0 |
30 Sep 21 | 1,069 | 445 | 533 | 0 |
30 Jun 21 | 1,032 | 365 | 491 | 0 |
31 Mar 21 | 1,045 | 402 | 445 | 0 |
31 Dec 20 | 1,046 | 407 | 433 | 0 |
30 Sep 20 | 1,042 | 93 | 428 | 0 |
30 Jun 20 | 1,006 | 205 | 400 | 0 |
31 Mar 20 | 887 | 177 | 384 | 0 |
31 Dec 19 | 788 | 37 | 354 | 0 |
30 Sep 19 | 675 | 21 | 322 | 0 |
30 Jun 19 | 605 | 18 | 298 | 0 |
31 Mar 19 | 519 | -39 | 278 | 0 |
31 Dec 18 | 451 | 21 | 249 | 0 |
30 Sep 18 | 414 | 10 | 236 | 17 |
30 Jun 18 | 323 | -52 | 220 | 32 |
31 Mar 18 | 233 | -106 | 200 | 48 |
31 Dec 17 | 162 | -143 | 170 | 0 |
30 Sep 17 | 67 | -194 | 137 | 90 |
30 Jun 17 | 6 | -220 | 111 | 88 |
31 Mar 17 | 0 | -200 | 84 | 90 |
31 Dec 16 | 15 | -141 | 68 | 58 |
30 Sep 16 | 15 | -126 | 53 | 57 |
30 Jun 16 | 15 | -123 | 47 | 58 |
31 Mar 16 | 15 | -107 | 39 | 52 |
31 Dec 15 | 20 | -89 | 32 | 48 |
30 Sep 15 | 20 | -79 | 29 | 44 |
30 Jun 15 | 20 | -60 | 22 | 37 |
31 Mar 15 | 20 | -50 | 19 | 34 |
31 Dec 14 | 0 | -61 | 18 | 32 |
30 Sep 14 | 1 | -52 | 16 | 29 |
30 Jun 14 | 1 | -47 | 15 | 27 |
31 Mar 14 | 2 | -46 | 14 | 26 |
31 Dec 13 | 3 | -46 | 13 | 25 |
30 Sep 13 | 24 | -26 | 13 | 25 |
Quality Earnings: NBIX has a large one-off loss of $176.3M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: NBIX's current net profit margins (16%) are higher than last year (10.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NBIX's earnings have grown by 13% per year over the past 5 years.
Accelerating Growth: NBIX's earnings growth over the past year (92.3%) exceeds its 5-year average (13% per year).
Earnings vs Industry: NBIX earnings growth over the past year (92.3%) exceeded the Biotechs industry 0.5%.
Return on Equity
High ROE: NBIX's Return on Equity (13.5%) is considered low.